3,4-Methylenedioxy-N-propylamphetamine

3,4-Methylenedioxy-N-propylamphetamine (MDPR, "Phantom") is a lesser-known psychedelic drug and a substituted amphetamine. MDPR was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 200 mg, and the duration unknown.^[1] MDPR is a promoter; by itself it has almost no effects on the mind, but it promotes the effects of hallucinogens, similarly to the closely related MDPH.

MDPR

Names
Preferred IUPAC name N-[1-(2H-1,3-Benzodioxol-5-yl)propan-2-yl]propan-1-amine
Identifiers
CAS Number	74698-36-5 Y
3D model (JSmol)	Interactive image
ChemSpider	486273
ECHA InfoCard	100.217.125
PubChem CID	559375
UNII	B4W69BKX3L Y
CompTox Dashboard (EPA)	DTXSID50339877
SMILES CC(NCCC)Cc1ccc2OCOc2c1
Properties
Chemical formula	C13H19NO2
Molar mass	221.300 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Y verify (what is YN ?) Infobox references

Shulgin reported that 160 mg of MDPR strongly enhanced the effects of a small (60 μg) dose of LSD,^[1] and that similar enhancement of hallucinogenic effect was noted when mixing MDPR with other drugs such as psilocybin, mescaline, 2C-B, and 2C-T-7. The reason for this synergistic action of MDPR has not been elucidated. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPR other than what is written in PiHKAL.

See also

• Phenylpropylaminopentane
• Benzofuranylpropylaminopentane
• Phenethylamine
• MDAL
• Psychedelic drug